Reviewing ICON Public (NASDAQ:ICLR) and ANGLE (OTCMKTS:ANPCY)

ICON Public (NASDAQ:ICLR) and ANGLE (OTCMKTS:ANPCY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares ICON Public and ANGLE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ICON Public	8.57%	12.06%	6.59%
ANGLE	N/A	N/A	N/A

Valuation and Earnings

This table compares ICON Public and ANGLE”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICON Public	$8.33 billion	2.83	$612.34 million	$8.22	34.75
ANGLE	N/A	N/A	N/A	C($0.48)	-2.65

ICON Public has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.6% of ICON Public shares are owned by institutional investors. 44.0% of ICON Public shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ICON Public and ANGLE, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICON Public	0	0	11	1	3.08
ANGLE	0	0	0	0	N/A

ICON Public presently has a consensus target price of $351.60, suggesting a potential upside of 23.10%. Given ICON Public’s higher probable upside, research analysts plainly believe ICON Public is more favorable than ANGLE.

Summary

ICON Public beats ANGLE on 11 of the 11 factors compared between the two stocks.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.